Relation between microRNAs and Apoptosis in Hepatocellular Carcinoma by Kamel, Refaat R. et al.
  
_______________________________________________________________________________________________________________________________ 
OA Maced J Med Sci. 2016 Mar 15; 4(1):31-37.                                                                                                                                                                               31 
 
ID Design 2012/DOOEL Skopje 
Open Access Macedonian Journal of Medical Sciences. 2016 Mar 15; 4(1):31-37. 
http://dx.doi.org/10.3889/oamjms.2016.038 
eISSN: 1857-9655 
Basic Science 
  
 
 
 
Relation between microRNAs and Apoptosis in Hepatocellular 
Carcinoma 
 
 
Refaat R. Kamel
1
, Khalda Said Amr
2
, Mie Afify
3
, Yasser A. Elhosary
4
, Abdelfattah E. Hegazy
5
, Hoda H. Fahim
6
, Wafaa M. 
Ezzat
4*
 
 
1
Surgery Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt; 
2
Medical Molecular Genetics Department, 
National Research Center, Cairo, Egypt; 
3
Biochemistry Department, National Research Centre, Cairo, Egypt; 
4
Internal 
Medicine Department, National Research Centre, Cairo, Egypt; 
5
Surgery Department, Elsahel Teaching Hospital, Cairo, 
Egypt; 
6
Anesthesia Department, Elsahel Teaching Hospital, Cairo, Egypt 
 
 
Citation: Kamel RR, Amr KS, Afify M, Elhosary JA, 
Hegazy AE, Fahim HH, Ezzat WM. Relation between 
microRNAs and Apoptosis in Hepatocellular Carcinoma. 
OA Maced J Med Sci. 2016 Mar 15; 4(1):31-37. 
http://dx.doi.org/10.3889/oamjms.2016.038 
Key words: HCC; apoptosis; pathogenesis; microRNAs; 
HCV. 
*Correspondence: Dr. Wafaa M Ezzat. National 
Research Center, Internal Medicine, Cairo 12311, Egypt. 
E-Mail: wafaa_3t@yahoo.com 
Received: 13-Feb-2016; Revised: 28-Feb-2016; 
Accepted: 29-Feb-2016; Online first: 09-Mar-2016 
Copyright: © 2016 Refaat R. Kamel, Khalda Said Amr, 
Mie Afify, Yasser A. Elhosary, Abdelfattah E. Hegazy, 
Hoda H. Fahim, Wafaa M. Ezzat. This is an open access 
article distributed under the terms of the Creative 
Commons Attribution License, which permits unrestricted 
use, distribution, and reproduction in any medium, 
provided the original author and source are credited. 
Competing Interests: The authors have declared that no 
competing interests exist. 
 
 
 
 
 
 
 
 
 
 
 
Abstract  
AIM: To determine the relation between serum microRNAs and apoptotic markers as regards 
development of HCC to understand the underlying mechanism of HCV related 
hepatocarcinogenesis.  
PATIENTS AND METHODS: A total of 65 serum samples (25 samples from controls, 20 samples 
from hepatitis and 20 samples from HCC patients) were collected for miRNAs (mir 21, mir 199-a, 
and mir 155) detection. Human Programmed cell death protein-4 (PDCD-4) and Human 
Cytochrome-C (CYT-C) were determined.  
RESULTS: miRNAs 21 and 155 were over expressed in sera of patients with HCC compared to 
patients with chronic hepatitis (p < 0.0001). While serum means values of miR 199a was 
significantly decreased among HCC group patients when compared to patients with chronic 
hepatitis (p < 0.0001). The serum levels of PCDC4 and CYTC were increased in patients with HCC 
when compared to chronic hepatitis patients. They were also increased in patients with chronic 
hepatitis when compared to controls (p < 0.05, significant). There was direct correlations between 
apoptotic markers and oncomirs miRNAs 21 and 155 while apoptotic markers were inversely 
correlated with miRNA 199-a.  
CONCLUSION: Both microRNAs and apoptotic markers have roles in HCC pathogenesis. It seems 
that oncogenic microRNAs induce liver carcinogenesis in HCV patients irrespective of suppression 
of apoptosis. 
 
 
 
 
 
Introduction 
 
Liver cancer is one of the most common 
malignancies all over the world and among the 
important causes of malignancy-related death [1]. 
Similar to other malignancies, the pathogenesis of 
liver cancer is a complex with contribution of genetic 
and epigenetic changes [2]. 
MicroRNAs (miRNAs) are a class of 
phylogenetically conserved short RNAs that suppress 
protein expression through base-pairing with the 3’-
untranslated region (3’-UTR) of target mRNA [3]. 
Many studies suggest that miRNAs act significant 
roles in diverse biological processes and the 
dysfunction of miRNAs is included in the cancer 
development [4]. 
Cell cycle dysregulation is an important step 
in the induction and development of human 
malignancies, including liver cancer. Accumulating 
evidence has shown that deregulated miRNAs may 
affect HCC cell proliferation through direct interaction 
with critical regulators of cell cycle machinery [5]. 
Apoptosis is a natural barrier to tumorigenesis 
and malinancy progression. Cancer cells struggle to 
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avoid apoptosis to escape from the supervision of the 
body and to survive in the difficult tumor environment 
[6]. 
There are many miRNAs that target anti-
apoptotic members of the Bcl-2 family. Most are 
significantly downregulated in HCC. For instance, 
miR-16 and miR-29 are down regulated in HepG2 
cells, and one of their target genes is confirmed to be 
Bcl-2 [7]. There are some other miRNAs whose target 
gene is Mcl-1. Apart from silencing of Bcl-2, miR-29 
can also directly target Mcl-1 in mitochondrion-
mediated apoptotic pathway [8]. In addition, miR-101, 
miR-193b, miR-125b, and let-7c, which are 
downregulated in HCC cells, might exert anti-
apoptotic action via targeting Mcl-1 [9]. 
Xiong and his colleagues have reported a 
significant down-regulation of miR-29 family members, 
including miR-29a, miR-29b, and miR-29c (miR-
29a/b/c), in tissues of liver cancer [10]. This is in 
accordance with previous observations in other types 
of human neoplasm [11]. It has been shown that 
ectopic expression of miR-29b inhibits cell growth and 
promotes tumor necrosis factor–related apoptosis 
inducing ligand–triggered apoptosis [12]. 
In this study, we found differentially 
deregulated microRNAs (mir21; mir199-a; mir155) 
among patients with HCV related hepatocellular 
carcinoma. Moreover, apoptotic markers: 
Programmed Cell Death Protein 4 (PDCD4) and 
Cytochrome C (CYTC) were up regulated in the same 
patients. Here we try to clarify the relation between 
serum microRNAs and apoptotic markers as regards 
development of HCC to understand the underlying 
mechanism of HCV related hepatocarcinogenesis. 
 
 
Patients and Methods 
 
Between June 2011 and June 2013, a total of 
65serum samples (25 samples from controls, 20 
samples from hepatitis and 20 samples from HCC 
patients) were collected from patients who underwent 
liver resection or living donor liver transplantation 
(LDLT) at the First Affiliated El Sahahel Teaching 
Hospital and Dr. Refaat Kamel Hospital (Cairo, 
Egypt). Serum samples were also collected from 25 
healthy volunteers who served as control group. All of 
the HCC patients were diagnosed by liver biopsy or by 
the findings of at least two radiological tests of HCC, 
including abdominal ultrasound, magnetic resonance 
imaging (MRI), hepatic angiography and contrast-
enhanced dynamic computed tomography or by 
increased AFP (AFP ≥200 μg/mL). Patients with 
secondary or recurrent tumors, a history of other 
malignant tumors; patients with hepatitis B virus 
infection or being included in other studies were 
excluded from this study. For the 20 chronic hepatitis 
cases, the diagnosis was based on the serum tests. 
Serum hepatitis B surface antigens (HBsAg) and anti-
HCV antibody were assayed by microparticle enzyme 
immunoassay using commercial kits to determine 
hepatitis B or hepatitis C infection. A total of 25 
cancer-free controls were attached at the physical 
examination center. Controls that had clinical liver 
diseases were excluded. The current study was 
approved by Ethical Committee of National Research 
Center. After signing an informed consent, all subjects 
were asked to fill a questionnaire to investigate the 
demographic characteristics, disease history, and the 
history of cancer and alcohol or tobacco use. Consent 
to publish data of the current research was obtained 
from every participant. The clinical characteristics 
including tumor differentiation, tumor size, metastasis, 
Child-Pugh class, were collected from medical 
records. 
 
miRNA extraction and quantification 
Isolation of miRNAs from blood of patients 
and controls followed the protocol for miRNeasy RNA 
isolation kit (Qiagen, Germany). Separation of serum 
took place immediately within 2 h from blood sample 
collection. The extracted total RNA including miRNA 
from tissue and serum are subjected to reverse 
transcription. 
 
RT-PCR 
TaqMan miRNA assays (Life Technologies, 
CA) were used to quantify the expression levels of 
mature miR-122 Total RNA extracted by miRvana (life 
technologies) was reverse transcribed in reaction 
mixture containing miR-specific stem-loop RT primers. 
Quantitative real time polymerase chain reaction 
(qPCR) was performed with 3 microliter of each cDNA 
on aStep One TM Plus Real-Time PCR System (ABI) 
in duplicates reactions containing the prepared cDNA 
and TaqMan specific primers in Universal Master Mix 
without Amp Erase UNG (Applied Biosystems) and 
threshold cycles (CT) were calculated using 
Sequence Detection Software (SDS v2.2.1, Applied 
Biosystem). All mRNA quantification data were 
normalized to 18S RNA. All miRNA data are 
expressed relative to a RNU48 small nuclear (sn)RNA 
TaqMan PCR performed on the same samples. Fold 
expression was calculated from the mean CT values 
using the 22DDCt method. Relative quantity (RQ) of 
miRNAs 21 and 199-a was calculated by the formula 
(RQ=2−ΔΔCt), where Ct is defined as the fractional 
cycle number at which the fluorescence generated by 
cleavage of the probe passes a fixed threshold above 
baseline. 
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Detection of Human Programmed cell death 
protein-4 (PDCD-4) and Human Cytochrome-
C (CYT-C) in blood samples (serum) 
 Detection of apoptotic markers in serum was 
carried out using this assay employed the quantitative 
sandwich enzyme immunoassay technique. The kits 
(Glory Science Co., Ltd, USA) use double – antibody 
sandwich enzyme- linked immunosorbent assay 
(ELISA) to assay the level of Human Programmed cell 
death protein 4 (PDCD4) and Human Cytochrome C 
(CYTC) in blood samples (serum). The procedure for 
each parameter is as follows: 
 Add PDCD4 to monoclonal antibody Enzyme 
well which is pre-coated with Human 
Programmed cell death protein monoclonal 
antibody, incubation; , or add CYTC to 
monoclonal antibody Enzyme well which is 
pre-coated with Human cytochrome C 
monoclonal antibody; then  
 Add PDCD4 or Cytochrome c (CYTC) 
antibodies labeled with biotin, and combined 
with Streptavidin-HRP to form immune 
complex; then carry out incubation and 
washing again to remove the uncombined 
enzyme. Then add Chromogen Solution A, B, 
the color of the liquid changes into the blue, 
and the effect of acid, the color finally 
becomes yellow. The chroma of color and the 
concentrations of the human substance 
Programmed cell death 4 (PDCD4) or 
Cytochrome C (CYTC) of sample were 
positively correlated.  
 We calculate the O.D value of all the wells 
with the standard and the wells with samples, 
make the standard curve diagram with 
concentration of the standard from the low to 
the high and the left to the right as abscissa 
{X} and O.D values of the wells at 450nm as 
ordinate {Y} axis.  
 Then find out the corresponding concentration 
range of each sample on this standard curve 
diagram according to their O.D values. 
 
Statistical analysis 
Data are expressed as mean ± SD unless 
otherwise indicated. Categorical data are described as 
frequency of the subjects with a specific characteristic. 
Chi-square test or Fisher’s exact test was used for 
comparing categorical data and Student’s t-test, 
Mann-Whitney-U-test, one-way ANOVA or Kruskal-
Wallis test, when appropriate, was used for comparing 
continuous variables. Two-tailed p-values less than 
0.05 were considered statistically significant. 
Statistical analysis was performed using SPSS 
software version 12.0 (SPSS Inc., Chicago, IL, USA). 
 
Results 
 
General characteristics for the studied 
patients 
Two groups of chronic HCV patients were 
enrolled in the current study; HCC group consists of 
20 patients, 19 males and one female with mean age 
of 56.25 ± 8.13 years. Chronic hepatitis group 
consists of 20 patients, 15 males and 5 females with 
mean age of 46.22 ± 8.45years. Frequency of past 
history of Schistosomiasis was 55% among HCC 
group while it was 60% among patients of chronic 
hepatitis group as shown in Table 1. There were no 
any significant differences between two studied 
groups of patients as regards liver function tests. As a 
traditional marker for HCC, AFP was significantly 
increased among HCC group of patients. Macroscopic 
examination of hepatocellular malignant lesions 
revealed that distribution of these lesions were more 
prevalent in both right and left lobes, then the right 
lobe and were least found in left lobe with mean size 
of 3.65 ± 1.75 cm. the frequency of single lesion was 
more than that of multiple lesions.  
Table 1: Demographic; clinical; biochemical and pathological 
data of the two studied groups of patients 
Variables HCC group 
N= 20 
Chronic hepatitis 
group 
N= 20 
Age in year’s     mean± SD.    56.25 ± 8.13 46.22 ± 8.45 
Sex 
Male     No (%) 
Female:  No (%) 
 
19 (95) 
1 (5 ) 
 
15(75) 
5 (25) 
PH of anti-Sch. ttt. 
Negative   No (%) 
Positive    No (%) 
 
9 (45) 
11 (55) 
 
8 (40) 
12 (60) 
AST    IU/L                 median (range).      98 (33-300) 53 (33-83) 
ALT   IU/L                  median(range) 35.6 (16-221) 57 (28-192) 
Albumin gm/dl            median(range) 2.5 (1.5-3.2) 2.8 (1.8-3.5) 
Total bilirubin  mg/dl  median(range) 1.6 (1-2.2) 1.4 (1-2.2) 
AFP    ng/ml               median (range).   21 (8-7460) 5 (1.30-75) 
CHOL    mg/dl            mean ± SD.   108.00 ± 16.35 121.66 ± 33.29 
TRG       mg/dl            mean ± SD.   91.20 ± 44.69 74.00 ± 13.11 
HDL       mg/dl            mean ± SD.   41.00 ± 18.29 28.00 ± 15.11 
LDL        mg/dl           mean ± SD.   42.30 ± 18.46 114.00 ± 16.35 
HCC lesions 
 Number: 
1    No (%) 
                 Multiple            No (%) 
Site:          
                 Rt. lobe No (%) 
                 Lt. lobe No (%) 
                 Both      No (%) 
Size  cm       
Grade : 
                 І     No (%) 
                 П   No (%) 
Type:  
                 Trabecular   No (%) 
                 Mixed        No (%)         
 
 
9 (45) 
11 (55) 
 
7 (35) 
1 (5) 
12 (60) 
3.65 ± 1.75 
 
4  (20) 
16 (80) 
 
8  (40) 
12 (60) 
 
Liver background : 
1-Mixed cirrhosis with mild activity          No (%) 
2-Mixed cirrhosis with moderate activity No (%)  
 
2   (10) 
 
18 (90) 
 
5  (25) 
 
15 (75) 
PH of anti-Sch. ttt: past history of antischistosomal treatment. AST: aspartate 
transaminase; ALT: alanine transaminase; AFP: α-fetoprotein; CHOL: cholesterol; TRG: 
triglycerides; HDL: high density lipoprotein; LDL: low density lipoprotein. 
 
 
microRNAs expression 
Calculated RQ expression of miRNAs 
21;199a and 155 revealed that miRNAs 21 and 155 
were over expressed in sera of patients with HCC 
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compared to patients with chronic hepatitis (p < 
0.0001) (Table 2). While serums mean values of miR 
199a was significantly decreased among HCC group 
patients when compared to patients with chronic 
hepatitis (p < 0.0001) (Table 2). Correlation of serum 
miR 21 to age; tumor size and biochemical and 
molecular investigations revealed that miR 21 was 
directly correlated to α-fetoprotein (P = 0.006, 
significant); HDL (p < 0.0001, highly significant); miR -
199 was inversely correlated to α-fetoprotein (P = 
0.009, significant); miRNA 155 as directly correlated 
to α-fetoprotein (p = 0.001, significant) and serum total 
bilirubin (p = 0.037, significant). Otherwise, there was 
no significant correlation of serum miRNAs to other 
studied variables. There were no significant impacts of 
tumor characters as regards number; site; size and 
microscopic features on serum or tissue expression of 
both studied miRNAs. 
Table 2: Comparison between HCC group and chronic hepatitis 
group as regards mean values of serum mirNAs and apoptotic 
markers 
mirRNAs 
(Mean ± SD) 
HCC group 
N = 20 
Chronic hepatitis group 
N = 20 
Controls 
N = 25 
P value 
Serum miR 21 7.76 ± 2.66 2.96 ± 1.92 1.2 ± 0.8 0.0001** 
Serum miR 199-a 0.79 ± 0.62 2.15 ± 1.048 2.5 ± 1.01 0.0001** 
Serum miR 155 10.25 ± 3.31 5.18 ± 2.45 1.1 ± 0.7 0.0001** 
Serum PDCD4 12.78 ± 5.36 6.87 ± 1.76 4.37 ± 1.13 0.0001** 
Serum CYTC 12.29 ± 4.87 7.63 ± 1.92 4.09 ± 0.92 0.01* 
 
*: P value is significant; **: P value is  highly significant. 
 
Serum values of apoptotic markers 
We found that serum levels of PCDC4 and 
CYTC were increased in patients with HCC when 
compared to chronic hepatitis patients. They were 
also increased in patients with chronic hepatitis when 
compared to controls (p < 0.05, significant) as shown 
in Table 2. 
Correlations of apoptotic markers with clinical 
and biochemical investigations revealed that serum 
values of PDCD4 was directly correlated with age and 
α fetoprotein (p = 0.004; 0.029 respectively, 
significant). On the other hand, serum values of CYTC 
was inversely correlated with SGPT (p = 0.007, 
significant) and directly correlated with total serum 
bilirubin (p = 0.013, significant). Analyzing the impact 
of HCC characters on serum values of PDCD4 and 
CYTC proved that the mean values of both PDCD4 
and CYTC were significantly higher in cases with 
single lesion of HCC (p < 0.05, significant). Right lobe 
location of HCC lesions has highest mean values of 
PDCD4 (p < 0.05, significant). As regards grade of 
differentiation, grade П have higher mean values of 
CYTC (p < 0.05, significant). 
Correlations between apoptotic markers and 
miRNAs revealed that there was direct correlations 
between apoptotic markers and oncomirs miRNAs 21 
and 155 while apoptotic markers were inversely 
correlated with miRNA 199-a as shown in Table 3. 
 
Table 3: Correlations between serum mirNAs and apoptotic 
markers 
  
Variables Serum PDCD4 Serum CYTC 
Serum miR 21 
Mean ±SD 
R = 0.538** 
P = 0.0001 
R = 0 .570** 
P = 0.0001 
Serum miR 199-a 
Mean ±SD 
R = - 0.330* 
P = 0.041 
R = - 0.511** 
P = 0.001 
Serum miR 155 
Mean ±SD 
R  =0.575** 
P = 0.0001 
R = 0.334* 
P = 0.038 
 
*:P value is significant; **: P value is  highly significant. 
 
 
Diagnostic accuracy of both microRNAs and 
apoptotic markers for HCC 
As regards the diagnostic accuracy of the 
studied mirNAs and apoptotic markers for HCC, it was 
found that highest sensitivity was achieved by mir 21 
and α fetoprotein while least sensitivity was achieved 
by CYTC. Serum α-fetoprotein has the least specificity 
while mir 21 and CYTC have the highest specificity. 
Combining mirNAs with each other resulted in 100% 
sensitivity and specificity except combined miR199-a 
and miR 155 have 88.90% specificity. Combined 
PDCD4 and CYTC can diagnose HCC with 94.70% 
sensitivity and 88.90% specificity as shown in Table 4. 
Table 4: Diagnostic accuracy for both serum mirNAs and 
apoptotic markers as early detectors for HCC  
Group Parameter 
Area under 
the curve 
Cutoff 
value 
Sensitivity % Specificity % 
HCC 
 Serum miR 21 
 
0.981 3.800 100.0 % 88.90% 
Serum miR 199-a 
 
0.843 1.150 83.30% 77.80% 
Serum miR 155 0.907 6.300 94.40% 77.80% 
Serum PDCD4 0.895 8.337 89.50% 77.80% 
Serum CYTC 0.798 9.610 63.20% 88.90% 
Serum  
α-fetoprotein 
0.832 8.050 100.0 % 69.2 % 
combined miR 21 
and miR 199-a 
1.000  100.00% 100.00% 
combined miR 21 
and miR 155 
1.000  100.00% 100.00% 
combined miR199-a 
and miR 155 
0.987  100.00% 88.90% 
Combined PDCD4 
and CYTC 
0.918  94.70% 88.90% 
 
 
 
Discussion 
 
One hundred seventies (170) million people 
are infected with Hepatitis C virus (HCV) all over the 
world [13]. Progression of hepatic inflammation to liver 
fibrosis, advanced fibrosis and liver cirrhosis present 
the platform for HCC development [14]. It was 
supposed that contribution of the apoptotic process 
during liver fibro genesis may be important for 
chronicity persistence, failure of response to antiviral 
drugs, fibrosis progression, and liver carcinogenesis 
[15]. 
It was found that miRNAs represents the 
genetic signature for many diseases including liver 
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cancer [16]. miRNAs usually target many genes, half 
of these genes are located in cancer-associated 
regions, including common chromosomal breakpoints, 
regions of loss of heterozygosity (LOH), amplified 
regions, fragile sites and hotspots for papilloma virus 
integration sites [17]. 
Apoptosis counterbalance the cell proliferation; so 
that, it is important for tissue homeostasis. Some of 
miRNAs influence cancer development might be by 
regulating apoptosis. This was approved by many 
studies [18]. 
Hou et al. used NGS, which is a high-
throughput technology that supplies universal 
information on all miRNAs in only one sample [19]. 
They investigated the miRNomes in human normal 
liver, inflamed liver due to viral hepatitis, and liver 
cancer. They found nine miRNAs accounted for 
~88.2% of the miRNome in human liver. The three 
most represented miRNAs were mRr-122, miR-192, 
and miR 199 a/b-3p. In HCC miR-199a/b-3p is 
lowered, this is accompanied with bad prognosis. 
Moreover, both in vitro and in vivo, the 
PAK4/Raf/MEK/ERK pathway is inhibited by miR-
199a/b-3p targeting tumor-promoting PAK4 to 
suppress HCC growth. 
We suggest that rate of hepatocyte death 
increases during liver carcinogenesis and this may 
explain high serum levels of PCDC4 and CYTC 
among patients with chronic hepatitis and HCC. All 
HCC cases in the current study have liver cirrhosis as 
a background. This background with continuous 
progression of inflammation may have an impact on 
increased serum values of apoptotic markers among 
cirrhotic and malignant patients. 
Programmed cell death 4 (PDCD4) proteins is 
a translational repressor that blocks helicase activity 
leading to negative effects on/control of the inception 
of mRNA translation [20]. Some studies have found a 
task for PDCD4 as a tumor oppressor that is missed 
in definite aggressive malignancies [21]. Surprisingly, 
recent evidence also proved that the mission of 
PDCD4 can be changed by the cofactor protein 
arginine methyltransferase 5 (PRMT5) and that 
arginine methylation of PDCD4 leads to progression 
of malignant transformation [22]. Therefore, there is 
strong evidence that PDCD4 has a serious role in the 
regulation of carcinogenesis and that its deregulation 
has significant outcome in cell growth and 
carcinogenesis. 
In our clinical practice, we find that late 
diagnosed HCC is an aggressive disease with high 
mortality rate; decreased survival rate and poor 
prognosis. So that search for novel molecular 
biomarkers for early detection of HCC will equal early 
therapeutic intervention; increased survival rate; better 
prognosis with improved quality of life for these 
patients. 
In the current study, we research for the 
relation between serum values of microRNAs and 
serum values of apoptotic markers in a trial to provide 
an in-depth view of genetic alteration patterns 
occurring in HCC and enable the discovery the 
mechanism by which microRNAs act in pathogenesis 
of HCC that might potentially be new diagnostic and/ 
or targets for HCC treatment 
We found that apoptotic markers were directly 
correlated with oncomirs 21 and 155 while they were 
inversely correlated with tumor suppressor mir 199-a. 
Our findings were against findings of previous studies, 
as Chu and his colleagues who reported that 
oncomirs inhibit apoptosis and down regulated 
miRNAs induce apoptosis during pathogenesis of 
HCC [23]. 
Zhu and his colleagues demonstrated that 
miR-21 was increased in liver cancer tissues and cell 
lines and was a strong stimulator of the 
migrative/invasive abilities of malignant liver cells. 
They also proved that a miR-21 inhibitor restricted 
HepG2 cell immigration and metastasis by 
direct/indirect control of PDCD4 and downstream 
signaling pathway molecules (p-c-Jun/AP-1, MMP-2 
and MMP-9), and that the transcription factor AP-1 
directly activates miR-21 transcription. They, therefor, 
suggest that a positive feedback loop of miR-21-
PDCD4-AP-1 maintains the miR-21-mediated 
biological effects of the liver cancer phenotype. They 
concluded that molecular introduction design 
interfering with the miR-21-PDCD4-AP-1 feedback 
loop might supply strong base for inhibiting 
invasion/metastasis in liver cancer in the near future 
[24]. 
Cheng and his colleagues used antisense 
RNA library to specifically knock down 90 human 
miRNAs in two different cell lines – HeLa (cervical 
carcinoma) and A549(lung carcinoma) – and tested 
for alterations in cell proliferation or apoptosis. In 
HeLa cells, inhibition of 19 miRNAs led to reduced cell 
growth, while inhibition of two miRNAs, miR-21 and 
miR-24, resulted in greater cell growth. Interestingly, 
inhibition of miR-24 in A549cell s led to the complete 
opposite phenotype: significant decreased of cell 
proliferation [25]. 
This result supposed that depending on the 
cellular environment or context, the same miRNA may 
have totally different effects. The ant proliferative 
activity of miR-21 in HeLa cells is also intriguing, 
because miR-21 has been proved to act as an ant 
apoptotic factor in human glioblastoma cells; 
therefore, one would have expected inhibition of miR-
21 to result in a reduction of cell growth. Finally, 
inhibition of miR-21 in A549cells did not lead to either 
specific up- or downregulation of cell proliferation. 
Therefore, likely to miR-24, miR-21 might have 
different tasks in different organs. Cheng and his 
colleagues also reported that inhibition of seven 
miRNAs (miR-1d, 7, 148, 204, 210, 216 and 296) 
result in increased caspase-3 activity and one miRNA 
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(miR-214) results in reduced activity. How the various 
miRNAs affect apoptosis remains to be investigated. 
Nevertheless, these experiments show the potential of 
such global screens to detect important candidate 
miRNAs, which can then be investigated further using 
more significant procedures. As discussed above, 
miR-21 can also act as an antiapoptotic factor. 
Glioblastoma, a highly malignant human brain cancer, 
strongly increased miR-21. Chan and his colleagues 
found greatly elevated levels of miR-21 in human 
glioblastoma malignat tissues, in early-passage 
glioblastoma cultures and in six established 
glioblastoma cell lines. Knock down of miR-21 in 
cultured glioblastoma cells led to a marked decrease 
in cell number. This reduction was not due to large 
differences in cell growth, but rather due to an 
increase in apoptosis, as detected by caspase-3 and -
7 enzymatic activities and TdT-mediated dUTP nick-
end labeling (TUNEL) staining. How miR-21 down 
regulates apoptosis, and whether it acts directly or 
indirectly remains to be detected [26]. 
Palma and his colleagues reported an anti-
leukaemic role for miR-155 in human FLT3-wildtype 
AML, by initiating cell apoptosis and myelomonocytic 
differentiation, which is in contrast to its previously 
suggested role as an oncogene. This highlights the 
complexity of gene regulation by microRNAs that 
depending on disease context or tissue type may 
have tumor repressor or oncogenic effects [27]. Here 
in the current study we can report that deregulation of 
the studied microRNAs have significant roles in 
development of HCC. They are powerful early 
diagnostic noninvasive markers for HCC. HCC usually 
develops on cirrhosis in cases of HCV infection as we 
found that liver background among HCC patients was 
mixed cirrhosis and the activity was mostly moderate 
which support that the process of inflammation in 
patients with HCV related HCC is continuous. The 
underlying mechanism for liver carcinogenesis is 
completely complex.so that, elevated serum apoptotic 
markers among HCC patients may be referred to 
continuous inflammatory process of underlying 
cirrhosis. According to our findings, it seems that 
oncogenic microRNAs induce liver carcinogenesis in 
HCV patients irrespective of suppression of apoptosis 
and the down regulated microRNA did not induce 
apoptosis to control tumorigenesis among HCV 
patients. We can suggest another explanation for the 
relation between microRNAs and apoptotic markers in 
the present study which is the process of underlying 
inflammation during HCV infection is not only 
continuous but it also exceeds the process of 
carcinogenesis. However, our findings may pave the 
way for search for treatment that target apoptosis with 
treatment target overexpressed or replace down 
regulated microRNAs to control the underlying 
mediators of HCC pathogenesis. 
 In conclusion, both microRNAs and apoptotic 
markers have roles in HCC pathogenesis. They could 
be used as early diagnostic markers for HCC. Further 
efforts must be paid to pave the way for emerging 
therapies to target apoptotic markers and expressed 
micoRNAs to control HCC development. 
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